Published on 18 Jul 2024Expansion of the Leadership TeamJohn P. O’Donnell has joined the company as Chief Development Officer, in the newly formed subsidiary of AUROBAC THERAPEUTICS in…
Published on 20 Jun 2024Appointment of Scientific Advisory BoardThe newly formed SAB chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s R&D strategy.
Published on 03 Jun 2024Presentation of our R&D Strategy and Pipeline – Announcement of a New Development ProgramAUROBAC’s strategy aims to address high unmet medical needs associated with infections in acute hospital settings, amidst the growing antimicrobial…
Published on 24 Jul 20232 new Independent Board Members: Manos Perros & Marco Taglietti"We are thrilled to welcome Dr Manos Perros as our new Chairman of the Board and Dr Marco Taglietti as…
Published on 13 Feb 2023Appointment of Martin Everett as Chief Scientific OfficerCommenting on the appointment, AUROBAC THERAPEUTICS CEO Florence Séjourné: “I am delighted that Martin is joining us. His incredibly strong…
Published on 04 Oct 2022Appointment of Florence Séjourné as Chief Executive Officer“Florence’s is an experienced biotech leader with outstanding strategic and operational acumen. The Board has great confidence in her to…